M&A Deal Summary |
|
|---|---|
| Date | 2019-11-11 |
| Target | Kyowa Pharmaceutical |
| Sector | Life Science |
| Buyer(s) | Unison Capital |
| Sellers(s) | Lupin |
| Deal Type | Secondary Buyout |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 1998 |
| PE ASSETS | 3.6B USD |
| Size | Large |
| Type | Sector Agnostic |
Unison Capital is a private equity investment firm focused on control investments in mid-cap companies operating in Japan, Korea, and Singapore. Target transaction situations include growth support, business successions, corporate carve-outs, buyouts, and restructurings. Unison is a generalist investor, however the Firm has a preference for opportunities in the retail, niche manufacturing, and healthcare sectors. Unison Capital was formed in 1998 and has offices in Tokyo, Seoul, and Singapore.
| DEAL STATS | # |
|---|---|
| Overall | 34 of 49 |
| Sector: Life Science M&A | 4 of 4 |
| Type: Secondary Buyout M&A Deals | 5 of 6 |
| Country: Japan M&A | 30 of 35 |
| Year: 2019 M&A | 3 of 5 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-06-21 |
Pyuru
Itoshima, Japan Pyuru specializes in the manufacture and sale of hair care and cosmetic products, with a focus on naturally-derived and additive-free ingredients. Pyuru “Rishiri Hair Color” brand has solidified a No.1 position within the gray hair color treatment market in Japan. Pyuru was founded in 1998 and is based in Itoshima, Japan. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-12-01 |
Medit
Seoul, South Korea Medit is a provider of 3D measurement and CAD/CAM solutions. Medit specializes in model and impression 3D scanners for dental clinics and labs, including intraoral scanners, based on our own patented state-of-the-art technology. Medit was founded in 2000 and is based in Seoul, South Korea. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1968 |
| Sector | Life Science |
| Employees | 24,006 |
| Revenue | 221.9B INR (2025) |
Lupin is an innovation-led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products. Lupin was founded in 1968 and is based in Mumbai, Maharashtra.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Life Science M&A | 1 of 2 |
| Type: Secondary Buyout M&A Deals | 1 of 1 |
| Country: Japan M&A | 1 of 1 |
| Year: 2019 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-10-11 |
Symbiomix Therapeutics
Newark, New Jersey, United States Symbiomix Therapeutics is a privately held company focused on bringing innovative therapies to market for gynecologic infections that can have serious health consequences. Symbiomix Therapeutics was founded in 2012 and is based in Newark, New Jersey. |
Buy | $150M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-07-15 |
Lupin s U.S. Commercial Women s Health Specialty Business
Baltimore, Maryland, United States Lupin's U.S. Commercial Women's Health Specialty Business is focused on commercializing SOLOSEC (secnidazole) 2g oral granules. It is an FDA-approved single-dose antimicrobial agent that provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections. |
Sell | - |
